HIV pre-treatment genotypic resistance has been reported in less than 0·1% of users of pre-exposure prophylaxis (PrEP) because of the effectiveness of PrEP in preventing HIV transmission. However, in the subgroup of PrEP users that do acquire HIV, genotypic resistance in 20 (29%) of 68 patients has been documented, and data on how to manage this group are in short supply. In this Correspondence, we present real-life, baseline resistance data comparing previous users of PrEP (tenofovir disoproxil fumarate and emtricitabine) and non-PrEP users, which were obtained from patients with newly diagnosed HIV at a sexual health and HIV clinic in central London, UK. We also describe the management and outcomes of these patients.

中文翻译：

---

预暴露于预防后的抗逆转录病毒耐药性和管理。

据报道，由于 PrEP 在预防 HIV 传播方面的有效性，暴露前预防 (PrEP) 使用者中不到 0·1% 的用户报告了 HIV 治疗前基因型耐药。然而，在确实感染 HIV 的 PrEP 使用者亚组中，68 名患者中有 20 名（29%）的基因型耐药已被记录，并且关于如何管理该组的数据短缺。在本通讯中，我们提供了现实生活中的基线耐药数据，比较了之前使用 PrEP（富马酸替诺福韦酯和恩曲他滨）和非 PrEP 用户的数据，这些数据来自伦敦市中心一家性健康和 HIV 诊所的新诊断 HIV 患者， 英国。我们还描述了这些患者的管理和结果。